Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

AFMD Affimed N.V. NKMax America to study AFM24,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 19
Posts 1,517
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/19/2021 4:17:40 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 4:27:32 PM
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additio... GlobeNewswire Inc. - 1/15/2021 9:21:32 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/14/2021 5:16:43 PM
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares GlobeNewswire Inc. - 1/13/2021 6:15:00 AM
Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire Inc. - 1/12/2021 4:01:00 PM
Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/11/2021 6:45:00 AM
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank GlobeNewswire Inc. - 1/11/2021 6:30:00 AM
Affimed Announces Pipeline and Business Update GlobeNewswire Inc. - 1/7/2021 6:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/18/2020 4:14:43 PM
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstratin... GlobeNewswire Inc. - 12/7/2020 10:01:00 AM
Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s a... GlobeNewswire Inc. - 11/19/2020 4:01:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 8:22:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/10/2020 8:15:33 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 6:34:41 AM
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress GlobeNewswire Inc. - 11/10/2020 6:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/9/2020 4:32:37 PM
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Inna... GlobeNewswire Inc. - 11/9/2020 4:01:00 PM
New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Na... GlobeNewswire Inc. - 11/9/2020 8:20:00 AM
Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapi... GlobeNewswire Inc. - 11/5/2020 4:01:00 PM
Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting an... GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Affimed to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 11/4/2020 6:30:00 AM
Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020 GlobeNewswire Inc. - 11/3/2020 6:30:00 AM
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:10 AM
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:00 AM
stockguard   Tuesday, 10/20/20 04:16:31 PM
Re: None
Post # of 237 
AFMD Affimed N.V. NKMax America to study AFM24, SNK01 combination
Affimed N.V. and NKMax America announced that they entered into a clinical collaboration agreement to investigate the combination of AFM24, a CD16A/EGFR-targeted ICE, with the autologous NK cell product SNK01. Pursuant to the collaboration, the companies plan to explore the combination in a first-in-human proof-of-concept trial in patients with EGFR-expressing tumors. The agreement follows a previous collaboration between the two companies in the preclinical setting to better understand the combined activity of their respective platforms. The results of the preclinical collaboration have shown substantive synergy between Affimed's ICE molecules and NKMax America's autolo gous and cryopreserved allogeneic natural killer cell products. Under the agreement, the companies will contribute their respective product candidates and resources towards submitting an Investigational New Drug application to the U.S. FDA and a subsequent clinical trial. The clinical trial will combine NKMax America's SNK01 with AFM24 in the autologous setting with the option to expand the clinical trial to the allogeneic setting. The cost of the clinical study will be shared by Affimed and NKMax America. The agreement also provides for the opportunity to pursue further clinical study combinations with additional product candidates from both parties.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences